Enrichment of CD4+ CD25high T Cell Population in Patients with Systemic Lupus Erythematosus Treated with Glucocorticoids

Overview

Journal Ann Rheum Dis

Specialty Rheumatology

Date 2006 Apr 12

PMID 16606650

Citations 58

Authors

A Suarez

P Lopez

J Gomez

C Gutierrez

Affiliations

Soon will be listed here.

Abstract

Objectives: To characterise and quantify the CD4+ CD25+ T cell population in patients with systemic lupus erythematosus (SLE) and to detect the possible influence of treatments and clinical manifestations.

Methods: Characterisation of CD25(low) and CD25(high) CD4+ T cells from healthy controls and from patients with SLE was carried out using flow cytometry, analysing the expression of activation and differentiation markers. The percentage of both circulating cell subsets was determined in 56 controls and 110 unselected patients with SLE. Data were related to treatment during the past 3 months and to various clinical manifestations.

Results: CD4+ CD25(high) lymphocytes from controls expressed low levels of CD69, CD154 or CD30, but also expressed glucocorticoid-induced tumour necrosis factor receptor, high levels of intracellular cytotoxin T lymphocyte-associated antigen 4, CD45RO and diminished amounts of CD4, all of which are phenotypic characteristics of natural regulatory T cells. CD4+ CD25(low) cells, on the other hand, expressed the highest levels of activation markers, indicating that they represent recently activated effector cells. Similarly, analysis of cells from patients with SLE showed the same two phenotypically distinguishable CD4+ CD25(low) and CD4+ CD25(high) populations, although both expressed slightly increased levels of activation markers. Quantitative analysis showed a considerably raised percentage of CD25(low) and, especially, CD25(high) cells in patients with SLE compared with controls. This increment was unrelated to clinical manifestations, but correlated with glucocorticoid treatment. Patients treated with glucocorticoids presented raised levels of CD25(high) cells, whereas untreated patients and those with anti-malarial or immunosuppressive drugs had levels similar to those in controls.

Conclusions: The percentage of CD4+ CD25(high) cells was not altered in non-steroid-treated patients, whereas glucocorticoid treatment increased their frequency in patients with SLE.

Citing Articles

Augmenting regulatory T cells: new therapeutic strategy for rheumatoid arthritis.

Zhang J, Liu H, Chen Y, Liu H, Zhang S, Yin G Front Immunol. 2024; 15:1312919.

PMID: 38322264 PMC: 10844451. DOI: 10.3389/fimmu.2024.1312919.

The frequency of Treg subsets distinguishes disease activity in ANCA vasculitis.

Agosto-Burgos C, Wu E, Iannone M, Hu Y, Hogan S, Henderson C Clin Transl Immunology. 2022; 11(11):e1428.

PMID: 36381498 PMC: 9652144. DOI: 10.1002/cti2.1428.

Circulating Th2 cell reduction and Th1/Th2 imbalance are correlated with primary Sjogren's syndrome-associated interstitial lung disease.

Shi L, Wang J, Guo H, Han X, Tang Y, Liu G Arthritis Res Ther. 2022; 24(1):121.

PMID: 35606782 PMC: 9125859. DOI: 10.1186/s13075-022-02811-z.

Associations of lymphocyte subpopulations with clinical phenotypes and long-term outcomes in juvenile-onset systemic lupus erythematosus.

Lerkvaleekul B, Apiwattanakul N, Tangnararatchakit K, Jirapattananon N, Srisala S, Vilaiyuk S PLoS One. 2022; 17(2):e0263536.

PMID: 35130317 PMC: 8820627. DOI: 10.1371/journal.pone.0263536.

Lupus nephritis with corticosteroid responsiveness: molecular changes of CD46-mediated type 1 regulatory T cells.

Tsai Y, Chien J, Chiu Y, Su T, Chiu P, Hsiao K Pediatr Res. 2021; 92(4):1099-1107.

PMID: 34952938 DOI: 10.1038/s41390-021-01882-z.

References

Su C, Shau W, Wang C, Chuang C, Chen C . CD69 to CD3 ratio of peripheral blood mononuclear cells as a marker to monitor systemic lupus erythematosus disease activity. Lupus. 1997; 6(5):449-54. DOI: 10.1177/096120339700600507. View

Longhi M, Ma Y, Bogdanos D, Cheeseman P, Mieli-Vergani G, Vergani D . Impairment of CD4(+)CD25(+) regulatory T-cells in autoimmune liver disease. J Hepatol. 2004; 41(1):31-7. DOI: 10.1016/j.jhep.2004.03.008. View

Lopez P, Mozo L, Gutierrez C, Suarez A . Epidemiology of systemic lupus erythematosus in a northern Spanish population: gender and age influence on immunological features. Lupus. 2003; 12(11):860-5. DOI: 10.1191/0961203303lu469xx. View

Kriegel M, Lohmann T, Gabler C, Blank N, Kalden J, Lorenz H . Defective suppressor function of human CD4+ CD25+ regulatory T cells in autoimmune polyglandular syndrome type II. J Exp Med. 2004; 199(9):1285-91. PMC: 2211900. DOI: 10.1084/jem.20032158. View

Gottenberg J, Lavie F, Abbed K, Gasnault J, Le Nevot E, Delfraissy J . CD4 CD25high regulatory T cells are not impaired in patients with primary Sjögren's syndrome. J Autoimmun. 2005; 24(3):235-42. DOI: 10.1016/j.jaut.2005.01.015. View

van Amelsfort J, Jacobs K, Bijlsma J, Lafeber F, Taams L . CD4(+)CD25(+) regulatory T cells in rheumatoid arthritis: differences in the presence, phenotype, and function between peripheral blood and synovial fluid. Arthritis Rheum. 2004; 50(9):2775-85. DOI: 10.1002/art.20499. View

Liu M, Wang C, Fung L, Wu C . Decreased CD4+CD25+ T cells in peripheral blood of patients with systemic lupus erythematosus. Scand J Immunol. 2004; 59(2):198-202. DOI: 10.1111/j.0300-9475.2004.01370.x. View

Lindley S, Dayan C, Bishop A, Roep B, Peakman M, Tree T . Defective suppressor function in CD4(+)CD25(+) T-cells from patients with type 1 diabetes. Diabetes. 2004; 54(1):92-9. DOI: 10.2337/diabetes.54.1.92. View

Chung I, Dong H, Zhang X, Hassanein N, Howard O, Oppenheim J . Effects of IL-7 and dexamethasone: induction of CD25, the high affinity IL-2 receptor, on human CD4+ cells. Cell Immunol. 2005; 232(1-2):57-63. DOI: 10.1016/j.cellimm.2005.01.011. View

10.

Crispin J, Martinez A, Alcocer-Varela J . Quantification of regulatory T cells in patients with systemic lupus erythematosus. J Autoimmun. 2003; 21(3):273-6. DOI: 10.1016/s0896-8411(03)00121-5. View

11.

Putheti P, Pettersson A, Soderstrom M, Link H, Huang Y . Circulating CD4+CD25+ T regulatory cells are not altered in multiple sclerosis and unaffected by disease-modulating drugs. J Clin Immunol. 2004; 24(2):155-61. DOI: 10.1023/B:JOCI.0000019780.93817.82. View

12.

Polanczyk M, Carson B, Subramanian S, Afentoulis M, Vandenbark A, Ziegler S . Cutting edge: estrogen drives expansion of the CD4+CD25+ regulatory T cell compartment. J Immunol. 2004; 173(4):2227-30. DOI: 10.4049/jimmunol.173.4.2227. View

13.

Chen X, Murakami T, Oppenheim J, Howard O . Differential response of murine CD4+CD25+ and CD4+CD25- T cells to dexamethasone-induced cell death. Eur J Immunol. 2004; 34(3):859-869. DOI: 10.1002/eji.200324506. View

14.

De Berardinis P, Londei M, Kahan M, Balsano F, Kontiainen S, Gale E . The majority of the activated T cells in the blood of insulin-dependent diabetes mellitus (IDDM) patients are CD4+. Clin Exp Immunol. 1988; 73(2):255-9. PMC: 1541607. View

15.

Somerset D, Zheng Y, Kilby M, Sansom D, Drayson M . Normal human pregnancy is associated with an elevation in the immune suppressive CD25+ CD4+ regulatory T-cell subset. Immunology. 2004; 112(1):38-43. PMC: 1782465. DOI: 10.1111/j.1365-2567.2004.01869.x. View

16.

Zhan Y, Funda D, Every A, Fundova P, Purton J, Liddicoat D . TCR-mediated activation promotes GITR upregulation in T cells and resistance to glucocorticoid-induced death. Int Immunol. 2004; 16(9):1315-21. DOI: 10.1093/intimm/dxh134. View

17.

Kukreja A, Cost G, Marker J, Zhang C, Sun Z, Lin-Su K . Multiple immuno-regulatory defects in type-1 diabetes. J Clin Invest. 2002; 109(1):131-40. PMC: 150819. DOI: 10.1172/JCI13605. View

18.

Sanchez-Ramon S, Navarro A J, Aristimuno C, Rodriguez-Mahou M, Bellon J, Fernandez-Cruz E . Pregnancy-induced expansion of regulatory T-lymphocytes may mediate protection to multiple sclerosis activity. Immunol Lett. 2004; 96(2):195-201. DOI: 10.1016/j.imlet.2004.09.004. View

19.

Huang Y, Pirskanen R, Giscombe R, Link H, Lefvert A . Circulating CD4+CD25+ and CD4+CD25+ T cells in myasthenia gravis and in relation to thymectomy. Scand J Immunol. 2004; 59(4):408-14. DOI: 10.1111/j.0300-9475.2004.01410.x. View

20.

Viglietta V, Baecher-Allan C, Weiner H, Hafler D . Loss of functional suppression by CD4+CD25+ regulatory T cells in patients with multiple sclerosis. J Exp Med. 2004; 199(7):971-9. PMC: 2211881. DOI: 10.1084/jem.20031579. View